Drug-induced Osteoporosis: Mechanisms and Clinical Implications (Q37797670)

23 August 2017

title

Drug-induced osteoporosis: mechanisms and clinical implications (English)

1 reference

23 August 2017

Drug-induced Osteoporosis: Mechanisms and Clinical Implications (English)

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

27 July 2024

0 references

2

Ernesto Canalis

0 references

Andrea Giustina

3

object named as

Andrea Giustina

1 reference

23 August 2017

1

Gherardo Mazziotti

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20920685

27 July 2024

language of work or name

English

0 references

publication date

1 October 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0002934310004675?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

https://api.elsevier.com/content/article/PII:S0002934310004675?httpAccept=text/plain

27 July 2024

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

American Journal of Medicine

27 July 2024

published in

1 reference

23 August 2017

volume

123

1 reference

23 August 2017

issue

10

1 reference

23 August 2017

page(s)

877-884

1 reference

Glucocorticoid-induced osteoporosis: pathophysiology and therapy

23 August 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Use of oral corticosteroids and risk of fractures.

27 July 2024

2

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study

27 July 2024

3

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures

27 July 2024

4

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy

27 July 2024

5

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

US and UK guidelines for glucocorticoid-induced osteoporosis: similarities and differences

27 July 2024

6

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

The Comparative Efficacy of Drug Therapies Used for the Management of Corticosteroid-Induced Osteoporosis: A Meta-Regression

27 July 2024

8

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Teriparatide or alendronate in glucocorticoid-induced osteoporosis

27 July 2024

9

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Thyroxine prescription in the community: serum thyroid stimulating hormone level assays as an indicator of undertreatment or overtreatment

27 July 2024

10

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

The clinical significance of subclinical thyroid dysfunction

27 July 2024

11

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Thyroid hormones: beneficial or deleterious for bone?

27 July 2024

12

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.

27 July 2024

13

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Serum TSH values and risk of vertebral fractures in euthyroid post-menopausal women with low bone mineral density

27 July 2024

14

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Levothyroxine treatment and occurrence of fracture of the hip.

27 July 2024

15

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Risk for fracture in women with low serum levels of thyroid-stimulating hormone

27 July 2024

16

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate.

27 July 2024

17

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

27 July 2024

18

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Cancer treatment-related bone loss: a review and synthesis of the literature

27 July 2024

19

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates

27 July 2024

20

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

27 July 2024

21

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole

27 July 2024

22

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial

27 July 2024

23

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

27 July 2024

24

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

27 July 2024

25

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

27 July 2024

26

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

The effects of depot medroxyprogesterone acetate and intrauterine device use on fracture risk in Danish women

27 July 2024

28

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Recovery of bone density in women who stop using medroxyprogesterone acetate

27 July 2024

29

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer

27 July 2024

30

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Changes in bone mineral density and body composition during initial and long-term gonadotropin-releasing hormone agonist treatment for prostate carcinoma

27 July 2024

31

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer

27 July 2024

32

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Risk of fracture after androgen deprivation for prostate cancer

27 July 2024

33

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Incidence and risk factors for low trauma fractures in men with prostate cancer.

27 July 2024

34

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Approach to the prostate cancer patient with bone disease

27 July 2024

35

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8.

27 July 2024

36

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

27 July 2024

37

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial

27 July 2024

38

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study

27 July 2024

39

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

27 July 2024

40

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Bicalutamide monotherapy versus leuprolide monotherapy for prostate cancer: effects on bone mineral density and body composition

27 July 2024

41

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Mechanisms of anabolic therapies for osteoporosis

27 July 2024

42

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Growth hormone, insulin-like growth factors, and the skeleton

27 July 2024

43

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

PPAR-gamma regulates osteoclastogenesis in mice

27 July 2024

44

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Rosiglitazone-associated fractures in type 2 diabetes: an Analysis from A Diabetes Outcome Progression Trial (ADOPT).

27 July 2024

45

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Vertebral fractures in males with type 2 diabetes treated with rosiglitazone.

27 July 2024

46

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis

27 July 2024

47

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum

27 July 2024

48

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Effect of selective serotonin reuptake inhibitors on the risk of fracture

27 July 2024

49

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Anti-epileptic medication and bone health

27 July 2024

50

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

The effects of heparin and low molecular weight heparins on bone

27 July 2024

51

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin

27 July 2024

53

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts

27 July 2024

55

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Warfarin use and risk for osteoporosis in elderly women. Study of Osteoporotic Fractures Research Group

27 July 2024

57

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Single-point assessment of warfarin use and risk of osteoporosis in elderly men.

27 July 2024

58

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Heart failure is a risk factor for orthopedic fracture: a population-based analysis of 16,294 patients

27 July 2024

59

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide

27 July 2024

60

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Mapping the prescriptiome to fractures in men--a national analysis of prescription history and fracture risk

27 July 2024

61

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Loop diuretic use and fracture in postmenopausal women: findings from the Women's Health Initiative

27 July 2024

62

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Cyclosporin-A in vitro decreases bone resorption, osteoclast formation, and the fusion of cells of the monocyte-macrophage lineage

27 July 2024

63

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Cyclosporin A in the oophorectomized rat: unexpected severe bone resorption

27 July 2024

64

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Frequency and predictors of osteoporotic fractures after cardiac or liver transplantation: a follow-up study

27 July 2024

65

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Transplantation osteoporosis

27 July 2024

66

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Approach to the patient with transplantation-related bone loss

27 July 2024

67

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review

27 July 2024

68

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system

27 July 2024

69

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis

27 July 2024

70

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection

27 July 2024

71

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro

27 July 2024

72

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Long-term proton pump inhibitor therapy and risk of hip fracture

27 July 2024

73

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Increase in vertebral fracture risk in postmenopausal women using omeprazole

27 July 2024

74

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture

27 July 2024

75

1 reference

https://api.crossref.org/works/10.1016/J.AMJMED.2010.02.028

27 July 2024

Identifiers

1 reference

23 August 2017

1 reference